Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Selexis Inks Agreement With Sanofi | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Selexis Inks Agreement With Sanofi

Will develop cell lines for three Sanofi biologics programs

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis SA has entered three service agreements with Sanofi through which Selexis will develop research cell banks using its SUREtechnology Platform.

Under the three agreements, Selexis will develop: a cell line for a naked antibody; a new cell line for a bispecific antibody; and a new cell line for the expression of a complex recombinant vaccine protein.

“Our SUREtechnology Platform provides an option that biopharmaceutical companies may consider for developing both biologics and vaccine treatments,” said Marco Bocci, vice president, licensing and business development, Selexis. “It’s rewarding to work with Sanofi across multiple applications including vaccines.”

According to Selexis, its proprietary SUREtechnology Platform supports the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization.

“Selexis’ technologies are innovative and nimble. We adapt to the required needs of global biopharmaceutical companies with robust pipelines targeting multiple therapeutic areas and various modes of drug and vaccine development,” said Igor Fisch, chairman and chief executive officer, Selexis. “We offer a one-stop solution to our partners, and this model is validated by the continued expansion of our collaborations, many of which are long-term relationships as these companies advance their candidates through the clinical development process to biologics and vaccine manufacturing.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics